Sprout investors say Valeant overcharging for female libido pill – BenefitsPro


BenefitsPro

Sprout investors say Valeant overcharging for female libido pill
BenefitsPro
Investors in Sprout, the female libido pill maker bought by Valeant Pharmaceuticals International Inc. for $1 billion last year, said Valeant has failed to successfully commercialize the treatment by setting the price too high and neglecting to market
Valeant's Sprout ProblemBloomberg
Analysts Weigh In On Biotech Giants Valeant Pharmaceuticals Intl Inc (VRX) And Celgene Corporation (CELG)Smarter Analyst
VRX Stock Tanks Again Today After Hiking Drug Price 100%Money Morning
TheStreet.com –ValueWalk –FiercePharma
all 107 news articles »

Female libido pill symbolic of Valeant woes – Salt Lake Tribune


Bidness ETC

Female libido pill symbolic of Valeant woes
Salt Lake Tribune
Valeant Pharmaceuticals International's struggles to ramp up sales of its new female libido pill offer a window into the drugmaker's woes. The mail-order pharmacy that could have helped distribute the drug is now out of the picture following a scandal
Analyst's Avg Estimated EPS for Next Year? Valeant Pharmaceuticals (NYSE:VRX), Amgen (NASDAQ:AMGN)WsNews 4investors

all 179 news articles »

Safety concerns over female libido drug Addyi – CBS News


CBS News

Safety concerns over female libido drug Addyi
CBS News
The only female libido drug approved by the FDA appears to cause a host of side effects, while only marginally improving sexual satisfaction in those taking it, according to a new review published in JAMA Internal Medicine. Flibanserin, sold under the
Benefits of Taking Female Libido Drug Are 'Marginal' Says New AnalysisABC News
Analysis questions benefit of female libido drugFox News
Female Libido Pill Not Worth It: ResearchersNewsmax
New York Magazine
all 154 news articles »